

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

VISEN Pharmaceuticals
维昇药业
(incorporated in the Cayman Islands with limited liability)
(Stock code: 2561)

APPOINTMENT OF CHIEF FINANCIAL OFFICER

The board (the “**Board**”) of directors (the “**Directors**”) of VISEN Pharmaceuticals (the “**Company**”, and its subsidiaries, the “**Group**”) is pleased to announce that Mr. Lu Ying (“**Mr. Lu**”) has been appointed as the Chief Financial Officer of the Company with effect from October 13, 2025.

Mr. Lu Ying (陸楹), aged 41, has over 19 years of experience in financial management. Prior to joining our Group, Mr. Lu served as the chief financial officer of VivaVision Biotech Limited. (維眸生物科技(浙江)有限公司), a clinical-stage pharmaceutical company that develops innovative therapies for ocular diseases, from August 2021 to October 2025, overseeing corporate finance, investor relations and financial management. Prior to that, he served as the financial director of Allergan Information Consulting (Shanghai) Co., Ltd. (艾爾建信息諮詢(上海)有限公司) from August 2020 to August 2021, responsible for financial management, strategic planning, internal control and post-merger integration. Mr. Lu held various financial management positions within the group of Bayer A.G. from September 2010 to August 2020, with his last position being the chief financial officer of BAYER HEALTHCARE LIMITED (拜耳醫療保健有限公司), where he was mainly responsible for overall financial management, budgeting and forecasting, internal control, and business integration across Bayer’s healthcare business in Hong Kong. In his early career, Mr. Lu served as a senior associate at PricewaterhouseCoopers Zhong Tian LLP (普華永道中天會計師事務所(特殊普通合夥)) from August 2006 to February 2010.

Mr. Lu obtained Bachelor of Arts degree in business English from Shanghai University of Finance and Economics (上海財經大學) in June 2006.

The Board would like to extend its warmest welcome to Mr. Lu on his appointment.

By order of the Board
VISEN Pharmaceuticals
Mr. LU An-Bang
Executive Director and Chief Executive Officer

Hong Kong, October 13, 2025

As at the date of this announcement, the board of directors of the Company comprises (i) Mr. LU An-Bang as executive director; (ii) Mr. FU Shan and Mr. CAO Yibo as non-executive directors; and (iii) Dr. YAO Zhengbin (Bing), Mr. CHAN Peng Kuan, Ms. NI Hong and Mr. ZHANG Qing as independent non-executive directors.